Robatumumab
Robatumumab Basic information
- Product Name:
- Robatumumab
- Synonyms:
-
- Robatumumab
- Research Grade Robatumumab(DHC29906)
- Research Grade Robatumumab
- Robatumumab (anti-IGF1R)
- CAS:
- 934235-44-6
- MW:
- 0
- Mol File:
- Mol File
Robatumumab Chemical Properties
- form
- Liquid
- color
- Colorless to light yellow
Robatumumab Usage And Synthesis
Uses
Robatumumab (Sch 717454) is an anti-human IGF-1R (insulin-like growth factor receptor-1) antibody. Robatumumab shows anti-tumor activity and anti-proliferative activity to cancer cells. Robatumumab can be used in osteosarcoma and Ewing sarcoma research[1][2].
in vivo
Robatumumab (intravenous injection; 0.04 or 0.1 mg/mouse; twice weekly; 18 d) inhibits the SK-N-FI tumor growth in xenograft model[2].
Robatumumab (intravenous injection; 0.02-0.5 mg/mouse; twice weekly; 35 d) inhibits the osteosarcoma growth in xenograft model[2].
Robatumumab (intravenous injection; 0.1 or 0.5 mg/mouse; twice weekly; 14 d) inhibits the SJCRH30 and RD rhabdomyosarcoma cell growth in xenograft model[2].
Robatumumab (intravenous injection; 0.1 or 0.5 mg/mouse; twice weekly; 2 w) blocks effectively pediatric tumor cell proliferation in vivo[2].
Robatumumab (intravenous injection; 0.5 mg/mouse; once; day 11 post-inoculation) modulates the blood vessel formation via its antiangiogenesis effect[2].
| Animal Model: | Nude mice inoculated with SK-N-FI tumor cells[2] |
| Dosage: | 0.04 or 0.1 mg/mouse |
| Administration: | Intravenous injection; 0.04 or 0.1 mg/mouse; twice weekly; 18 days |
| Result: | Inhibited the SK-N-FI xenograft tumor by 96% in the 0.04 mg dose group and resulted in 11% tumor regression in the 0.1 mg dose group. |
| Animal Model: | Nude mice inoculated with SJSA-1 osteosarcoma[2] |
| Dosage: | 0.02, 0.1 or 0.5 mg/mouse |
| Administration: | Intravenous injection; 0.02, 0.1 or 0.5 mg/mouse; twice weekly; 35 days |
| Result: | Inhibited the tumor growth by 71%, 82%, and 88% at 0.02, 0.1, and 0.5 mg, respectively, at day 14 after treatment. |
| Animal Model: | Nude mice inoculated with SJCRH30 and RD rhabdomyosarcoma cells[2] |
| Dosage: | 0.1 or 0.5 mg/mouse |
| Administration: | Intravenous injection; 0.1 or 0.5 mg/mouse; twice weekly; 14 days |
| Result: | Inhibited tumor growth by 39% and 58% at 0.1 and 0.5 mg dose, respectively, in the RD rhabdomyosarcoma model. Inhibited tumor growth by 37% and 53% at 0.1 and 1 mg dose, respectively, in the SJCRH30 model. |
| Animal Model: | Nude mice inoculated with SK-N-FI neuroblastoma and SJSA-1 osteosarcoma[2] |
| Dosage: | 0.1 or 0.5 mg/mouse |
| Administration: | Intravenous injection; 0.1 or 0.5 mg/mouse; twice weekly; 2 weeks |
| Result: | Reduced the tumor Ki-67 staining by 38% and along with significant change in SK-N-FI neuroblastoma xenograft. Reduced the staining of Ki-67 by 37% and 51% after 0.1 and 0.5 mg SCH 717454 treatment, respectively, in the SJSA-1 osteosarcoma xenograft. |
| Animal Model: | Nude mice inoculated with SJSA-1 osteosarcoma[2] |
| Dosage: | 0.5 mg/mouse |
| Administration: | Intravenous injection; 0.5 mg/mouse; once; day 11 post-inoculation |
| Result: | Reduced in the intensity of the fluorescent lectin staining by 74% at 0.5 mg dose, showing thinner blood vessels and reduced branches, compared with control IgG1. |
References
[1] Anderson PM, et al. A phase II study of clinical activity of SCH 717454 (robatumumab) in patients with relapsed osteosarcoma and Ewing sarcoma. Pediatr Blood Cancer. 2016 Oct;63(10):1761-70. DOI:10.1002/pbc.26087
[2] Wang Y, et al. A fully human insulin-like growth factor-I receptor antibody SCH 717454 (Robatumumab) has antitumor activity as a single agent and in combination with cytotoxics in pediatric tumor xenografts. Mol Cancer Ther. 2010 Feb;9(2):410-8. DOI:10.1158/1535-7163.MCT-09-0555
RobatumumabSupplier
- Tel
- 021-61312847; 18021002903
- 3008007409@qq.com
- Tel
- 177-54423994 17754423994
- 2853530910@QQ.com
- Tel
- 15817493340
- 981810490@qq.com
- Tel
- 027-65317797 15926423062
- 422450190@qq.com
- Tel
- 4008200310
- marketing@tsbiochem.com